Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Third-line therapy for chronic myeloid leukemia: current status and future directions
Jorge E. Cortés, Fabian Lang
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 93

Showing 26-50 of 93 citing articles:

Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights
Miriam Iezza, Sofia Cortesi, Emanuela Ottaviani, et al.
Cells (2023) Vol. 12, Iss. 13, pp. 1703-1703
Open Access | Times Cited: 9
Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid Leukemia
Zafar Iqbal, Muhammad Absar, Tanveer Akhtar, et al.
Biology (2021) Vol. 10, Iss. 11, pp. 1182-1182
Open Access | Times Cited: 20
Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases
Ying Fei Li, François Pierre Combes, Matthias Hoch, et al.
Clinical Pharmacokinetics (2022) Vol. 61, Iss. 10, pp. 1393-1403
Closed Access | Times Cited: 13
Chronic myeloid leukemia: cytogenetics and molecular biology’s part in the comprehension and management of the pathology and treatment evolution
Sara Benchikh, Amale Bousfiha, Adil El Hamouchi, et al.
Egyptian Journal of Medical Human Genetics (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 12
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Dachuan Zeng, Miao Gao, Renren Zheng, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 12
1,4-Naphthoquinone (CNN1) Induces Apoptosis through DNA Damage and Promotes Upregulation of H2AFX in Leukemia Multidrug Resistant Cell Line
Adrhyann Jullyanne de Sousa Portilho, Emerson Lucena da Silva, Emanuel Cintra Austregésilo Bezerra, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8105-8105
Open Access | Times Cited: 12
Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells
Seiichi Okabe, Mitsuru Moriyama, Akihiko Gotoh
World Journal of Oncology (2024) Vol. 15, Iss. 2, pp. 319-324
Open Access | Times Cited: 2
Dynamic Single-Cell RNA-Seq reveals mechanism of Selinexor-Resistance in Chronic myeloid leukemia
Yunqi Cui, Yating Li, Jiamei Ji, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112212-112212
Open Access | Times Cited: 2
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial
Ehab Atallah, Michael J. Mauro, Koji Sasaki, et al.
Future Oncology (2024), pp. 1-11
Open Access | Times Cited: 2
Understanding and Monitoring Chronic Myeloid Leukemia Blast Crisis: How to Better Manage Patients
Lulu Wang, Li Li, Rongrong Chen, et al.
Cancer Management and Research (2021) Vol. Volume 13, pp. 4987-5000
Open Access | Times Cited: 15
Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy
Massimo Breccia, Francesca Chiodi, Aurelio Pio Nardozza, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 13, pp. 3597-3597
Open Access | Times Cited: 11
Asciminib for chronic myeloid leukaemia: Next questions
Naranie Shanmuganathan, Timothy P. Hughes
British Journal of Haematology (2022) Vol. 199, Iss. 3, pp. 322-331
Closed Access | Times Cited: 10
Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
Camille Kockerols, Jeroen J.W.M. Janssen, Nicole M. A. Blijlevens, et al.
Haematologica (2022) Vol. 108, Iss. 1, pp. 240-244
Open Access | Times Cited: 10
Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment
Danlin Yao, Jing Lai, Yuhong Lu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
Congying Gao, Lei Zhang, Yun Xu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
The importance of personalized medicine in chronic myeloid leukemia management: a narrative review
Erfan Zaker, Negar Nouri, Sepehr Sorkhizadeh, et al.
Egyptian Journal of Medical Human Genetics (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review
Ehab Atallah, Lovneet Saini, Rodrigo Maegawa, et al.
Therapeutic Advances in Hematology (2023) Vol. 14
Open Access | Times Cited: 5
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies
John Joson Ng, S. Tiong Ong
Current Hematologic Malignancy Reports (2022) Vol. 17, Iss. 6, pp. 181-197
Closed Access | Times Cited: 9
8-Hydroxydaidzein Downregulates JAK/STAT, MMP, Oxidative Phosphorylation, and PI3K/AKT Pathways in K562 Cells
Pei‐Shan Wu, Chih‐Yang Wang, Pin-Shern Chen, et al.
Biomedicines (2021) Vol. 9, Iss. 12, pp. 1907-1907
Open Access | Times Cited: 11
Growth Inhibitory and Pro-Apoptotic Effects of Hirsuteine in Chronic Myeloid Leukemia Cells through Targeting Sphingosine Kinase 1
Shan Gao, Tingting Guo, Shuyu Luo, et al.
Biomolecules & Therapeutics (2022) Vol. 30, Iss. 6, pp. 553-561
Open Access | Times Cited: 8
Asciminib as a third line option in chronic myeloid leukemia
Alessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.
International Journal of Hematology (2022) Vol. 117, Iss. 1, pp. 16-23
Closed Access | Times Cited: 8
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial
Jorge E. Cortés, Andreas Hochhaus, Naoto Takahashi, et al.
Future Oncology (2022) Vol. 18, Iss. 38, pp. 4161-4170
Open Access | Times Cited: 8
Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes
Nobuko Hijiya, Michael J. Mauro
Cancer Management and Research (2023) Vol. Volume 15, pp. 873-891
Open Access | Times Cited: 4
Design, in silico Evaluation, and Determination of Antitumor Activity of Potential Inhibitors Against Protein Kinases: Application to BCR-ABL Tyrosine Kinase
Е. В. Королева, А. L. Ermolinskaya, Zhanna V. Ignatovich, et al.
Biochemistry (Moscow) (2024) Vol. 89, Iss. 6, pp. 1094-1108
Closed Access | Times Cited: 1
FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation
Gulsum E. Pamuk, Edwin C.Y. Chow, Alexei Ionan, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 19, pp. 4266-4271
Closed Access | Times Cited: 1

Scroll to top